GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (SZSE:300759) » Definitions » Cash Conversion Cycle

Pharmaron Beijing Co (SZSE:300759) Cash Conversion Cycle : 106.60 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Pharmaron Beijing Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 73.95.
Pharmaron Beijing Co's Days Inventory for the three months ended in Mar. 2024 was 52.88.
Pharmaron Beijing Co's Days Payable for the three months ended in Mar. 2024 was 20.23.
Therefore, Pharmaron Beijing Co's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 106.60.


Pharmaron Beijing Co Cash Conversion Cycle Historical Data

The historical data trend for Pharmaron Beijing Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Cash Conversion Cycle Chart

Pharmaron Beijing Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 74.86 76.11 73.93 83.38 95.66

Pharmaron Beijing Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.50 97.16 97.48 96.62 106.60

Competitive Comparison of Pharmaron Beijing Co's Cash Conversion Cycle

For the Biotechnology subindustry, Pharmaron Beijing Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaron Beijing Co's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Pharmaron Beijing Co's Cash Conversion Cycle falls into.



Pharmaron Beijing Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Pharmaron Beijing Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=65.23+50.58-20.15
=95.66

Pharmaron Beijing Co's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=73.95+52.88-20.23
=106.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaron Beijing Co  (SZSE:300759) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Pharmaron Beijing Co Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaron Beijing Co (SZSE:300759) Business Description

Traded in Other Exchanges
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.
Executives
Lou Xiao Qiang Directors, executives
Zheng Bei Directors, executives

Pharmaron Beijing Co (SZSE:300759) Headlines

No Headlines